Physician

General Surgery

Thomas Aloia practices General Surgery. He graduated from David Geffen School of Medicine at UCLA. David Geffen School of Medicine at UCLA is a top medical university. David Geffen School of Medicine at UCLA has a rank of 13 in research and a 7 in primary care He has 2 awards "Top Doctors:SE Texas" and "Fellow (FACS)". Thomas Aloia is a published doctor and has 102 publications published. The lastest was: 'RAS Mutation Predicts Positive Resection Margins and Narrower Resection Margins in Patients Undergoing Resection of Colorectal Liver Metastases.' He accepts Medicare payments and is registered with Medicare.gov.

Publications

---

• Laparoscopic Insulinoma Enucleation from the Retro-Pancreatic Neck: A Stepwise Approach.
• Transthoracic Port Placement Increases Safety of Total Laparoscopic Posterior Sectionectomy.
• Development and Feasibility of a Specialty-Specific National Surgical Quality Improvement Program (NSQIP): The Head and Neck-Reconstructive Surgery NSQIP.
• Impact of processes of care aimed at complication reduction on the cost of complex Cancer surgery.
• Advances in hepatectomy technique: Toward zero transfusions in the modern era of Liver surgery.
• Total Laparoscopic Central Pancreatectomy with Pancreaticogastrostomy for High-Risk Cystic Neoplasm.
• After Pancreatectomy, the "90 Days from Surgery" Definition Is Superior to the "30 Days from Discharge" Definition for Capture of Clinically Relevant Readmissions.
• Venous Thromboembolism Prophylaxis in Liver Surgery.
• Positive Impact of Epidural Analgesia on Oncologic Outcomes in Patients Undergoing Resection of Colorectal Liver Metastases.
• Efficacy and cost effectiveness of voriconazole prophylaxis for prevention of invasive aspergillosis in high-risk Liver transplant recipients.
• Ablative Radiotherapy Doses Lead to a Substantial Prolongation of Survival in Patients With Inoperable Intrahepatic Cholangiocarcinoma: A Retrospective Dose Response A...
• Rapid assessment of technical competency: the 8-min suture test.
• Parenchymal-sparing Hepatectomy in ColoRectal Liver Metastasis: Improves Salvageability and Survival.
• (18)F-FDG Uptake at the Surgical Margin after Hepatic Resection: Patterns of Uptake and Differential Diagnosis.
• Active Surveillance for Adverse Events Within 90 Days: The Standard for Reporting Surgical Outcomes After Pancreatectomy.
• Ninety-Day Postoperative Mortality Is a Legitimate Measure of HepatopancreatoBiliary Surgical Quality.
• Does the use of neoadjuvant therapy for Pancreatic adenocarcinoma increase postoperative morbidity and mortality rates?
• Volume regeneration of segments 2 and 3 after right portal vein embolization in patients undergoing two-stage hepatectomy.
• Characterization of Anthropometric Changes that Occur During Neoadjuvant Therapy for Potentially Resectable Pancreatic Cancer.
• Perioperative blood transfusion in gynecologic oncology surgery: Analysis of the National Surgical Quality Improvement Program Database.
• Is Complete Liver Resection Without Resection of Synchronous Lung Metastases Justified?
• RAS Mutations Predict Radiologic and Pathologic Response in Patients Treated with Chemotherapy Before Resection of ColoRectal Liver Metastases.
• Propensity Score-Matched Analysis of Comprehensive Local Therapy for Oligometastatic Non-Small Cell Lung Cancer That Did Not Progress After Front-Line Chemotherapy.
• Reoperative surgery: a critical risk factor for complications inadequately captured by operative reporting and coding of lysis of adhesions.
• Treatment sequencing strategy for hepatic epithelioid haemangioendothelioma.
• Role of Neoadjuvant Therapy in the Multimodality Treatment of Older Patients with Pancreatic Cancer.
• Simultaneous Lung resection via a transdiaphragmatic approach in patients undergoing liver resection for synchronous liver and Lung metastases.
• Return to intended oncologic treatment (RIOT): A novel metric for evaluating the quality of oncosurgical therapy for malignancy.
• Tumor Location Is a Strong Predictor of Tumor Progression and Survival in T2 Gallbladder Cancer: An International Multicenter Study.
• Development and Validation of Insulin-like Growth Factor-1 Score to Assess Hepatic Reserve in Hepatocellular Carcinoma.
• Efficacy and safety of portal vein embolization for two-stage hepatectomy in patients with coloRectal liver metastasis.
• Contemplation Documentation Before Surgery.
• Laparoscopic Intragastric Surgery for Early Gastric Cancer and Gastrointestinal Stromal Tumors.
• The influence of complications on the costs of complex Cancer surgery.
• Systematic use of an intraoperative air leak test at the time of major liver resection reduces the rate of postoperative Biliary complications.
• Morbidity and Mortality in 1,174 Patients Undergoing Hepatic Parenchymal Transection Using a Stapler Device.
• Treatment Sequencing for Resectable Pancreatic Cancer: Influence of Early Metastases and Surgical Complications on Multimodality Therapy Completion and Survival.
• Does laparoscopic adrenalectomy jeopardize oncologic outcomes for patients with adrenocortical carcinoma?
• Radiographic Tumor-Vein Interface as a Predictor of Intraoperative, Pathologic, and Oncologic Outcomes in Resectable and Borderline Resectable Pancreatic Cancer.
• RAS Mutation Status Predicts Survival and Patterns of Recurrence in Patients Undergoing Hepatectomy for ColoRectal Liver Metastases.
• Intrabiliary growth of coloRectal liver metastasis: spectrum of imaging findings and implications for surgical management.
• Perioperative Antimicrobial Prophylaxis for Intra-Abdominal Surgery in Patients with Cancer: A Retrospective Study Comparing Ertapenem and Nonertapenem Antibiotics.
• Safety and Efficacy of Portal Vein Embolization Before Planned Major or Extended Hepatectomy: An Institutional Experience of 358 Patients.
• Morbidity and Mortality after Pancreaticoduodenectomy in Patients with Borderline Resectable Type C Clinical Classification.
• Neoadjuvant radiation therapy and its impact on complications after pancreaticoduodenectomy for pancreatic cancer: Analysis of the American College of Surgeons Nationa...
• Prognostic Indicators and Treatment Outcome in 94 Cases of Fibrolamellar Hepatocellular Carcinoma.
• Predictors of morbidity and mortality after hepatectomy in elderly patients: Analysis of 7621 NSQIP patients.
• Serum carbohydrate antigen 19-9 represents a marker of response to neoadjuvant therapy in patients with borderline resectable pancreatic Cancer.
• Pre-transplant utilization of sorafenib is not associated with increased complications after Liver transplantation.
• Distinct predictors of pre- versus post-discharge venous thromboembolism after hepatectomy: Analysis of 7621 NSQIP patients.
• Predicting the risks of venous thromboembolism versus post-pancreatectomy haemorrhage: Analysis of 13 771 NSQIP patients.
• Modified cisplatin/interferon α-2b/doxorubicin/5-fluorouracil (PIAF) chemotherapy in patients with no hepatitis or cirrhosis is associated with improved response rate,...
• Resection of At-Risk Mesenteric Lymph Nodes Is Associated with Improved Survival in Patients with Small Bowel Neuroendocrine Tumors.
• Analysis of the Efficacy of Portal Vein Embolization for Patients with Extensive Liver Malignancy and Very Low Future Liver Remnant Volume, Including a Comparison with...
• Cross-sectional and Case-Control Analyses of the Association of Kidney Function Staging With Adverse Postoperative Outcomes in General and Vascular Surgery.
• Optimal Future Liver Remnant in Patients Treated with Extensive Preoperative Chemotherapy for ColoRectal Liver Metastases.
• Selection for hepatic resection of coloRectal liver metastases: expert consensus statement.
• Margin Status Remains an Important Determinant of Survival After Surgical Resection of ColoRectal Liver Metastases in the Era of Modern Chemotherapy.
• Kinetic Growth Rate after Portal Vein Embolization Predicts Posthepatectomy Outcomes: Toward Zero Liver-Related Mortality in Patients with ColoRectal Liver Metastases ...
• Microvascular Invasion Does Not Predict Long-Term Survival in Hepatocellular Carcinoma up to 2 cm: Reappraisal of the Staging System for Solitary Tumors.
• Optimal Morphologic Response to Preoperative Chemotherapy: An Alternate Outcome End Point Before Resection of Hepatic ColoRectal Metastases.
• ColoRectal Liver Metastases.
• KRAS mutation in coloRectal cancer metastases after adjuvant FOLFOX for the primary.
• Adjuvant Chemotherapy With FOLFOX for Primary ColoRectal Cancer Is Associated With Increased Somatic Gene Mutations and Inferior Survival in Patients Undergoing Hepate...
• Greater Complexity of Liver Surgery is Not Associated with an Increased Incidence of Liver-Related Complications Except for Bile Leak: An Experience with 2,628 Consecu...
• Improved Long-Term Survival after Major Resection for Hepatocellular Carcinoma: A Multicenter Analysis Based on a New Definition of Major Hepatectomy.
• Morbidity of Staged Proctectomy After Hepatectomy for Colorectal Cancer: A Matched Case-Control Analysis.
• Associating Liver Partition and Portal Vein Ligation for Staged Hepatectomy (ALPPS): What Is Gained and What Is Lost?
• Optimizing clinical and economic outcomes of surgical therapy for patients with coloRectal cancer and synchronous liver metastases.
• Risk of venous thromboembolism outweighs post-hepatectomy bleeding complications: Analysis of 5651 National Surgical Quality Improvement Program patients.
• Clinical and prognostic implications of plasma insulin-like growth factor-1 and Vascular endothelial growth factor in patients with hepatocellular carcinoma.
• I-CLIP: Improved Stratification of Advanced Hepatocellular Carcinoma Patients by Integrating Plasma IGF-1 into CLIP Score.
• Predicting adverse outcomes after complex Cancer surgery.
• Analysis of liver transplant outcomes for United Network for Organ Sharing recipients 60 years old or older identifies multiple model for end-stage liver disease-indep...
• Is hepatic resection justified after chemotherapy in patients with coloRectal liver metastases and lymph node involvement?
• A proposed staging system for intrahepatic cholangiocarcinoma.
• Is hepatic resection justified after chemotherapy in patients with coloRectal liver metastases and lymph node involvement?
• Analysis of recent pediatric orthotopic liver transplantation outcomes indicates that allograft type is no longer a predictor of survivals.
• Certificate of need regulations and the availability and use of Cancer resections.
• A decision Analysis model predicts the optimal treatment pathway for patients with colorectal cancer and resectable synchronous liver metastases.
• Outcomes Analysis for 280 patients with cholangiocarcinoma treated with liver transplantation over an 18-year period.
• Long-term outcomes following Liver transplantation for hepatic hemangioendothelioma: the UNOS experience from 1987 to 2005.
• A decision Analysis model identifies the interval of efficacy for transarterial chemoembolization (TACE) in cirrhotic patients with hepatocellular carcinoma awaiting l...
• High-resolution computed tomography accurately predicts resectability in hilar cholangiocarcinoma.
• Geographic disparities in deceased donor Liver transplantation within a single UNOS region.
• Delayed recovery after pancreaticoduodenectomy: a major factor impairing the deLivery of adjuvant therapy?
• Utility of computed tomography and magnetic resonance imaging staging before completion lymphadenectomy in patients with sentinel lymph node-positive melanoma.
• Hepatic resection for metastatic melanoma: distinct patterns of recurrence and prognosis for ocular versus cutaneous Disease.
• Solitary coloRectal liver metastasis: resection determines outcome.
• Predictors of outcome after hyperthermic isolated limb perfusion: role of tumor response.
• Two-surgeon technique for hepatic parenchymal transection of the noncirrhotic Liver using saline-linked cautery and ultrasonic dissection.
• Management of early-stage cutaneous melanoma.
• Surgical placement of biologic mesh spacers to displace bowel away from unresectable Liver tumors followed by deLivery of dose-intense radiation therapy.
• Gastric bleeding after radiation therapy for intrahepatic cholangiocarcinoma.
• Recent advances in the curative treatment of coloRectal liver metastases.
• Repeat hepatectomy for recurrent coloRectal liver metastases is associated with a high survival rate.
• Surgical treatment of hepatocellular Cancer: expert consensus conference.
• Management of coloRectal liver metastases: past, present, and future.
• A report of outcomes after orthotopic Liver transplant with allografts from heparin antibody-positive donors.
• RAS Mutation Predicts Positive Resection Margins and Narrower Resection Margins in Patients Undergoing Resection of ColoRectal Liver Metastases.
• Predictors of Safety and Efficacy of 2-Stage Hepatectomy for Bilateral ColoRectal Liver Metastases.

Schools

---

• David Geffen School Of Medicine At UCLA University Of California Los Angeles

• Duke University Med Center

• Paul Brousse Hospital

• University of Texas MD Anderson Cancer Center

Procedures Preformed

---

• Colectomy
• Enterostomy (Laparoscopic or Open)
• Excision of Bile Duct Tumor
• Excision of Stomach Tumor
• View All

Conditions Treated

---

• Abdominal Pain
• Anal and Rectal Cancer
• Atelectasis
• Bile Duct Cancer
• View All

Doctors Specialties

---

• General Surgery

Accepted Insurances

---

Awards

---

• Top Doctors:SE Texas
• Fellow (FACS)

Education

---

• University of Texas MD Anderson Cancer Center
• Duke University Hospital
• David Geffen School of Medicine at UCLA

Hospital

---

• University of Texas M.D. Anderson Cancer Center

Drug Facts

---

NPI NUMBER		1790724631
NPPES Provider LastName		ALOIA
NPPES Provider FirstName		THOMAS
NPPES Provider ZIPCode		770303722
NPPES Provider State		TX
Specialty Description		Surgical Oncology
Total Claim Count		17.0
Distinct Opioid Count		0.0
Opioid Claim Count		0.0
Percent Opioid Claims		0.0

Helpful Reviews

---

Give Anonymous Review

Medicare Facts

---

National Provider Identifier [NPI]	1790724631
Last Name Of The Provider	ALOIA
First Name Of The Provider	THOMAS
View All

Similar Doctors

---

	Dr. Mark McBath, MD This Doctor is OpenDoctor Recommended.
	Dr. Aquileo N. Hernandez, MD This Doctor is OpenDoctor Recommended.
	Dr. Kristofer M. Charlton-Ouw, MD This Doctor is OpenDoctor Recommended.
	Dr. Hoang L. Le, MD This Doctor is OpenDoctor Recommended.
	Dr. Gary B. Skakun, MD This Doctor is OpenDoctor Recommended.
	Dr. Mark H. Edelman, MD
	Dr. Nicole F. Ferriol, MD
	Dr. Vergel V. Cruz, MD
	Dr. Joseph F. Fernandez-Moure, MD
	Dr. Uma R. Phatak, MD
	Dr. Michele A. Riordon, MD
	Dr. Musiliu Olatoto, MD
	Dr. Bradford G. Scott, MD This Doctor is OpenDoctor Recommended.
	Dr. Nicole M. Tapia, MD This Doctor is OpenDoctor Recommended.
	Dr. Aaron Scott, MD
	Dr. Hector I. Saucedo Crespo, MD This Doctor is OpenDoctor Recommended.
	Dr. Sonja E. Singletary, MD This Doctor is OpenDoctor Recommended.

---

Doctor Directory | TOS | twitter | FB | Angel | blog